BIAMI: Body Impedance Analysis to Detect ICUAW

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05572138
Collaborator
(none)
50
1
2.9
17.1

Study Details

Study Description

Brief Summary

The aim of the study is to detect a value of muscle and organ mass measured by body impedance analysis and its correlation with the Medical Research Council (MRC) score. An MRC score ≤ 48 is defined as a diagnosis of ICU acquired weakness. The correlation of the values detected by BIA and their transfer to an MRC Score ≤ 48 will be investigated.

The knowledge gained will be used for early detection of ICUAW in order to reduce the consequences of the same.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Body Impedance Analysis

Detailed Description

Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of neuromuscular organ dysfunction. It develops in approximately 40% of all ICU patients, which corresponds to at least 1.2 million patients annually in Germany. All these patients face a wide spectrum of sequelae and increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is early severe muscle atrophy, which is as high as 17% in the first days after ICU admission.

ICUAW is currently diagnosed by the MRC score, which is assessed by the sum of manual muscle strength test results in 12 muscle groups (sum score). Manual muscle testing (MMT) is not possible during the early phase in critical illness in most patients due to coma, delirium, and/or injury. In addition, there is a possible discrepancy by different observers. As a result, early detection of ICUAW may be inadequate in most patients and unreliable during critical illness.

Measurement by BIA is reproducible, so differences in measurement can be attributed to changes in clinical condition. Body impedance analysis thus demonstrates a means of objective measurement.

Thus, the study aims to counteract the long-term consequences of ICUAW through early detection of ICUAW by allowing countermeasures to be taken earlier.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Body Impedance Analysis to Detect Muscle Strength Associated With ICU Acquired Weakness
Anticipated Study Start Date :
Feb 15, 2023
Anticipated Primary Completion Date :
Apr 15, 2023
Anticipated Study Completion Date :
May 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Critically ill patients

Diagnostic Test: Body Impedance Analysis
Body Impedance Analysis

Outcome Measures

Primary Outcome Measures

  1. Correlation: Skeletal muscle mass and MRC-Score [till Day 30]

    The primary endpoint is the correlation between Skeletal muscle mass (SMM) measured by BIA and MRC score.

Secondary Outcome Measures

  1. Correlation CSA and Skeletal muscle mass [till Day 30]

    Cross sectional area of muscle ultrasound (M. rectus femoris) and Skeletal muscle mass (SMM) measured by BIA

  2. UCR : MRC correlation [till Day 30]

    Correlation of urea-creatinine ratio in blood with MRC score.

  3. Kreatinin : MRC correlation [till Day 30]

    Correlation of creatinine in blood with MRC score.

  4. IMS during the ICU stay [till Day 30 or ICU discharge]

    achieved mobilization level during the ICU stay using the ICU Mobility Scale (IMS)

  5. ICU mortality [till Day 30]

    Mortality during ICU stay

  6. Duration of Mechanical ventilation [till Day 30]

    Duration of invasive mechanical ventilator dependency

  7. Hospital mortality [till Day 30]

    Mortality during Hospital stay

  8. ICU-LOS [till Day 30 (till ICU discharge)]

    Length of stay in the ICU

  9. Hospital LOS [till Day 30 (till hospital discharge)]

    Length of stay in the hospital

  10. in-hospital mortality [till Day 30 (till hospital discharge)]

    Mortality during the Hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged ≥ 18 years with ventilatory support within 36 hours from ICU admission.
Exclusion Criteria:
  • With a language barrier

  • Patients with pacemaker or other electronic implant

  • Expected death or discontinuation of life-sustaining measures.

  • Not walking independently before hospitalization (gait aids allowed)

  • Allergy to electrode gel

  • BIA or ultrasound not technically feasible due to e.g. extensive wounds, skin rash or bandages

Contacts and Locations

Locations

Site City State Country Postal Code
1 Charité - Univiversitätsmedizin Berlin Berlin Germany 10117

Sponsors and Collaborators

  • Charite University, Berlin, Germany

Investigators

  • Principal Investigator: Stefan J Schaller, MD, Charite University, Berlin, Germany

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Stefan J Schaller, Deputy Clinical Director, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT05572138
Other Study ID Numbers:
  • BIAMI
First Posted:
Oct 7, 2022
Last Update Posted:
Jan 31, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2023